RychikJVeldtmanGRandE, et al.The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol. 2012;33(7):1001–1012.
2.
SurreyLFRussoPRychikJ, et al.Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation. Hum Pathol. 2016;57:106–115.
3.
GoldbergDJSurreyLFGlatzAC, et al.Hepatic fibrosis is universal following Fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. J Am Heart Assoc. 2017;6(5):e004809.
4.
PossnerMGordon-WalkerTEgbeAC, et al.Hepatocellular carcinoma and the Fontan circulation: clinical presentation and outcomes. Int J Cardiol. 2021;322:142–148.
5.
RychikJAtzAMCelermajerDS, et al.Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019:CIR0000000000000696.
6.
SchwartzMCGlatzACDanielsK, et al.Hepatic abnormalities are present before and early after the Fontan operation. Ann Thorac Surg. 2015;100(6):2298–3204.
7.
TrustyPMWeiZARychikJ, et al.Cardiac magnetic resonance-derived metrics are predictive of liver fibrosis in Fontan patients. Ann Thorac Surg. 2020;109(6):1904–1911.
8.
PereiraRMdos SantosRAda Costa DiasFLTeixeiraMMSimoes e SilvaAC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol. 2009;15(21):2579–2586.
9.
SarafADe StaerckeCEverittI, et al.Biomarker profile in stable Fontan patients. Int J Cardiol. 2020;305:56–62.
10.
MainwaringRDLambertiJJMooreJWBillmanGFNelsonJC. Comparison of the hormonal response after bidirectional Glenn and Fontan procedures. Ann Thorac Surg. 1994;57(1):59–63; discussion 64.
11.
SugimotoMSaikiHTamaiA, et al.Ventricular fibrogenesis activity assessed by serum levels of procollagen type III N-terminal amino peptide during the staged Fontan procedure. J Thorac Cardiovasc Surg. 2016;151(6):1518–1526.
12.
EdensREGruberPJ. Fibrosis in Fontan physiology. J Thorac Cardiovasc Surg. 2016;151(6):1527–1528.
13.
KouatliAAGarciaJAZellersTMWeinsteinEMMahonyL. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96(5):1507–1512.
14.
HutchesonJDSetolaVRothBLMerrymanWD. Serotonin receptors and heart valve disease—it was meant 2B. Pharmacol Ther. 2011;132(2):146–157.
15.
XuJJianBChuR, et al.Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol. 2002;161(6):2209–2218.
16.
DolivoDMLarsonSADominkoT. Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis. Cell Mol Life Sci. 2018;75(20):3663–3681.
RuddellRGOakleyFHussainZ, et al.A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006;169(3):861–876.
19.
DeesCAkhmetshinaAZerrP, et al.Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208(5):961–972.
20.
ZeisbergEMTarnavskiOZeisbergM, et al.Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Medicine. 2007;13(8):952–961.
21.
SunSNingXZhangY, et al.Hypoxia-inducible factor-1 alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int. 2009;75(12):1278–1287.
22.
TraversJGKamalFARobbinsJYutzeyKEBlaxallBC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118(6):1021–1040.
23.
HoangTTMansoPHEdmanS, et al.Genetic variants of HIF1alpha are associated with right ventricular fibrotic load in repaired tetralogy of Fallot patients: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2019;21(1):51.
